[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 138, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 58, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 47, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Executive Director & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao Ph.D.", "age": 63, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 49, "title": "Senior Vice President of Bioinformatics & Information Technology", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 57, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 53, "title": "Senior Vice President of Early Drug Discovery", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 37, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jiping  Zha M.D., Ph.D.", "title": "Executive Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Songmao  Zheng Ph.D.", "title": "Senior VP of Clinical Pharmacology & Quantitative Sciences", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.77, "open": 1.74, "dayLow": 1.74, "dayHigh": 1.873, "regularMarketPreviousClose": 1.77, "regularMarketOpen": 1.74, "regularMarketDayLow": 1.74, "regularMarketDayHigh": 1.873, "payoutRatio": 0.0, "beta": 0.728, "forwardPE": -2.6086955, "volume": 3281289, "regularMarketVolume": 3281289, "averageVolume": 83388, "averageVolume10days": 106040, "averageDailyVolume10Day": 106040, "bid": 1.51, "ask": 1.99, "bidSize": 1, "askSize": 2, "marketCap": 84836288, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 3.16, "allTimeHigh": 31.83, "allTimeLow": 0.9, "priceToSalesTrailing12Months": 822.0252, "fiftyDayAverage": 1.87826, "twoHundredDayAverage": 1.86839, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 50067132, "profitMargins": 0.0, "floatShares": 14014483, "sharesOutstanding": 47131270, "sharesShort": 54899, "sharesShortPriorMonth": 72701, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0011999999, "heldPercentInsiders": 0.047, "heldPercentInstitutions": 0.30899, "shortRatio": 0.74, "shortPercentOfFloat": 0.0014, "impliedSharesOutstanding": 47131270, "bookValue": 0.804, "priceToBook": 2.2388058, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -29889636, "trailingEps": -0.64, "forwardEps": -0.69, "enterpriseToRevenue": 485.128, "enterpriseToEbitda": -1.528, "52WeekChange": -0.22026432, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 1.8, "targetHighPrice": 21.07, "targetLowPrice": 3.5, "targetMeanPrice": 9.26167, "targetMedianPrice": 7.5, "recommendationMean": 1.71429, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 62828156, "totalCashPerShare": 1.066, "ebitda": -32765248, "totalDebt": 6849932, "quickRatio": 2.203, "currentRatio": 2.292, "totalRevenue": 103204, "debtToEquity": 18.068, "revenuePerShare": 0.002, "returnOnAssets": -0.24893999, "returnOnEquity": -0.63259, "grossProfits": 103204, "freeCashflow": -17171550, "operatingCashflow": -27456540, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -322.83603, "financialCurrency": "USD", "symbol": "ADAG", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 83388, "fiftyTwoWeekLowChange": 0.5, "fiftyTwoWeekLowChangePercent": 0.3846154, "fiftyTwoWeekRange": "1.3 - 3.16", "fiftyTwoWeekHighChange": -1.3600001, "fiftyTwoWeekHighChangePercent": -0.43037978, "fiftyTwoWeekChangePercent": -22.026432, "earningsTimestampStart": 1753268340, "earningsTimestampEnd": 1753704000, "isEarningsDateEstimate": true, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": -3.3222172, "postMarketPrice": 1.7402, "postMarketChange": -0.05979991, "regularMarketChange": 0.029999971, "regularMarketDayRange": "1.74 - 1.873", "regularMarketChangePercent": 1.6949136, "regularMarketPrice": 1.8, "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1763768931, "regularMarketTime": 1763758800, "exchange": "NGM", "messageBoardId": "finmb_118162960", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -0.64, "epsForward": -0.69, "epsCurrentYear": -0.65, "priceEpsCurrentYear": -2.7692308, "fiftyDayAverageChange": -0.078260064, "fiftyDayAverageChangePercent": -0.041666258, "twoHundredDayAverageChange": -0.06839001, "twoHundredDayAverageChangePercent": -0.036603715, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-09", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "displayName": "Adagene", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]